The Schreiber group identified and validated neoepitopes in highly immunogenic carcinogen-induced sarcomas including neoantigens that enabled tumor rejection such as spectrin-β R913L, or were involved in tumor rejection in response to checkpoint inhibition such as neoepitopes derived from mutated LAMA4 or mutated ALG8 (104). This evidence concerns the gene LAMA4 and neoplasm.